Redwood Pharma’s CEO Martin Vidaeus in year-end interview
Stockholm, Sweden, December 20, 2023. Redwood Pharma AB (publ) today announces the publication of a sit-down interview performed by Finwire, where the company’s CEO Martin Vidaeus summarizes the year and looks ahead to an eventful year of 2024.
The interview is available at the company website and attached link:
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com
About Redwood Pharma
Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today's standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma's programs are based on IntelliGel - a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the first line treatment of dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The Company’s Certified Adviser is Carnegie Investment Bank AB (publ). For more information, visit www.redwoodpharma.com
